Technical Analysis for OTIC - Otonomy, Inc.

Grade Last Price % Change Price Change
F 2.23 1.36% 0.03
OTIC closed up 1.36 percent on Friday, April 9, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical OTIC trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 1.36%
Below Lower BB Weakness 1.36%
Down 3 Days in a Row Weakness 1.36%
Older End-of-Day Signals for OTIC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% 3 days ago
Up 2% 3 days ago
Rose Above Lower Bollinger Band 3 days ago
3x Volume Pace 3 days ago
2x Volume Pace 3 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Otonomy, Inc. develops and commercializes therapeutics for the treatment of ear diseases and disorders primarily in the United States. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which is in Phase III clinical trials to treat pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière's disease; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Clinical Development Surgery Antibiotic Disorders Otorhinolaryngology Tinnitus Dexamethasone

Is OTIC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.983
52 Week Low 1.96
Average Volume 1,295,697
200-Day Moving Average 4.08
50-Day Moving Average 3.48
20-Day Moving Average 2.65
10-Day Moving Average 2.51
Average True Range 0.21
ADX 27.47
+DI 15.32
-DI 32.49
Chandelier Exit (Long, 3 ATRs ) 2.36
Chandelier Exit (Short, 3 ATRs ) 2.83
Upper Bollinger Band 3.03
Lower Bollinger Band 2.26
Percent B (%b) -0.04
BandWidth 29.16
MACD Line -0.28
MACD Signal Line -0.30
MACD Histogram 0.0183
Fundamentals Value
Market Cap 107.55 Million
Num Shares 48.2 Million
EPS -1.60
Price-to-Earnings (P/E) Ratio -1.39
Price-to-Sales 542.55
Price-to-Book 3.08
PEG Ratio -0.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.35
Resistance 3 (R3) 2.35 2.32 2.33
Resistance 2 (R2) 2.32 2.29 2.32 2.32
Resistance 1 (R1) 2.27 2.27 2.27 2.27 2.32
Pivot Point 2.24 2.24 2.24 2.24 2.24
Support 1 (S1) 2.19 2.21 2.19 2.19 2.14
Support 2 (S2) 2.16 2.19 2.16 2.14
Support 3 (S3) 2.11 2.16 2.13
Support 4 (S4) 2.11